$PRVB This is a latest review of T1D interventions (link.springer.com/article/1...). Unfortunately you have to buy it. I did but it doesn’t allow forwarding. it discusses a larger number of treatments including natural ones. Basically concluding that challenges still remain. In the antibody section they mention Teplizumab and Abatacept. They say Teplizumab looks promising and waiting to see if new data can support wider use.
  • 6